Home
HelpTest Code LAB4368, LAB4388 TEG Heparin Neutralization
Additional Codes
CPT Codes per Test: 85347, 85576, 85384
Specimen Required
To ensure accurate results, draw a discard tube first. Use a no-additive tube or citrate tube marked “discard.” Note: using a plain serum tube for the discard draw is not recommended as these can contain clot activators.
Use only 3.2% sodium citrate Vacutainer tubes that have been filled completely (until vacuum is exhausted). After collection, gently invert the tube five times to mix. No additives or preservatives are necessary to maintain the integrity of the sample, but samples should normally be used after a 10-minute incubation and within two hours of draw. In an urgent or emergent situation, when speed to results is a concern, samples may be tested immediately.
Therapeutic Reference Ranges
CK-R (min) 4.6 - 9.1
CK-MA (mm) 52 - 69
CKH-R (min) 4.3 - 8.3
CKH-LY30 (%) 0 - 3.2
CRTH-MA (mm) 53 - 69
CFFH-MA (mm) 15 - 34
Coagulation Testing and Therapeutic Anticoagulant Recommendations
The TEG 6s Hemostasis System is intended for in vitro diagnostic use with adult patients where an evaluation of their blood hemostasis properties is desired. The Citrated: K, KH, RTH, FFH assay cartridge is intended to be used in monitoring of patients where heparin/heparinoids may be present and who are at an increased risk of coagulopathy.
Hemostasis evaluations are indicated to assess clinical conditions in cardiovascular surgery, cardiovascular procedures (e.g. minimally invasive valve replacement or repairs) and liver transplantation to assess hemorrhage or thrombosis conditions before, during and following the procedure.
Results from the TEG 6s analysis should not be the sole basis for a patient diagnosis, but should be evaluated together with the patient’s medical history, the clinical picture and, if necessary, further hemostasis tests.
The manufacturer’s hemostatic significance tables are available in PolicyStat in the assay procedure, and may be referred to by the provider to correlate potential heparin effect and how other assays available in-lab or at our reference laboratory may relate to the findings of this assay. The procedure also contains the manufacturer’s Method Comparison Study table, which may be referred to by the provider to consider if this test selection is proper and comparable to known methods/instruments. The procedure also contains the manufacturer’s Method Limitations tables, which may be referred to by the provider to determine if interferences or other limitations may affect the utility of this viscoelastic method.